Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

17
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
17
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

28
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
28
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

205
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
205
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

26
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pentose phosphate pathway contributes to excess lactate production in radiation-induced fibroblast to myofibroblast transdifferentiation.

The Journal of biological chemistry·2026
Same author

Establishing a Cervical Cytology Biorepository: A Protocol for Advancing Translational Cervical Cancer Research through Biobanking.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.

Circulation. Heart failure·2025
Same author

Depot-specific roles for sphingosine kinase 1 in conversion of white adipose to thermogenic adipose.

bioRxiv : the preprint server for biology·2025
Same author

The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation.

American journal of physiology. Renal physiology·2025
Same author

Phosphorylation of an RNA-Binding Protein Rck/Me31b by Hippo Is Essential for Adipose Tissue Aging.

Aging cell·2025

Related Experiment Video

Updated: Jul 29, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Circulating sphingolipids in heart failure.

Anna Kovilakath1, George Wohlford2, L Ashley Cowart3,4

  • 1Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States.

Frontiers in Cardiovascular Medicine
|May 25, 2023
PubMed
Summary
This summary is machine-generated.

Circulating sphingolipids show promise as early biomarkers for heart failure, signaling potential for new diagnostic tools and treatments. This review highlights their role in cardiac events and future research directions.

Keywords:
HFpEF—heart failure with preserved ejection fractionHFrEF—heart failure with reduced ejection fractionceramideceramide scoreheart failurelipidomicsserine palmitoyltransferasesphingolipid

More Related Videos

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

7.7K
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.5K

Related Experiment Videos

Last Updated: Jul 29, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K
Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

7.7K
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.5K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Biomarker Discovery

Background:

  • Heart failure lacks significant advancements in early detection and treatment.
  • Novel biomarkers and therapeutic targets are urgently needed.
  • Circulating sphingolipids have emerged as promising indicators of adverse cardiac events.

Purpose of the Study:

  • To review current literature on circulating sphingolipids in heart failure.
  • To explore the role of sphingolipids in human cohorts and animal models.
  • To guide future mechanistic studies and sphingolipid biomarker development.

Main Methods:

  • Literature review of human cohorts and animal models of heart failure.
  • Analysis of studies investigating circulating sphingolipids.
  • Synthesis of evidence linking sphingolipids to cardiac events.

Main Results:

  • Circulating sphingolipids show potential as biomarkers for predicting adverse cardiac events.
  • Evidence links sphingolipids directly to incident heart failure.
  • Studies in both human and animal models support the role of sphingolipids.

Conclusions:

  • Circulating sphingolipids are valuable in understanding heart failure pathogenesis.
  • Further research can establish sphingolipids as reliable biomarkers for early detection.
  • Sphingolipid-targeted therapies may offer new treatment avenues for heart failure.